$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
The effect of entrectinib/Luo Shengquan in the treatment of brain metastasis
2026-02-01 22:25:32
Check Details
Is brigatinib/brigatinib (Embry) safe to take long-term?
2026-02-01 22:25:32
Check Details
What diseases are specifically indicated for ibrutinib/Eco?
2026-02-01 22:25:32
Check Details
What to do after drug resistance to Ruxolitinib Tablets/Jiekewei
2026-02-01 22:25:32
Check Details
The combined therapeutic effect of clofazimine and bedaquiline
2026-02-01 22:25:32
Check Details
What are the side effects of sevabertinib-Hyrnuo?
2026-02-01 22:25:32
Check Details
How to refer to the usage and dosage guide of Sorafenib/Nexavar
2026-02-01 22:25:32
Check Details
The miraculous efficacy of Pemetinib/Dabotan in tumor treatment
2026-02-01 22:25:32
Check Details
How much does a complete course of Erdafitinib cost?
2026-02-01 22:25:32
Check Details
What should you pay attention to when taking dacomitinib/dacomitinib (Dozerun)?
2026-02-01 22:25:32
Check Details
The latest selling price per box of Entrectinib in 2025
2026-02-01 22:25:32
Check Details
Dosage and usage of sevabertinib-Hyrnuo
2026-02-01 22:25:32
Check Details
1
2
...
2320
2321
2322
2323
2324
2325
2326
...
10228
10229
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Asciminib (Scemblix): Targeted Mechanism, Dosing Regimens, and Missed-Dose Guidance
2
Vigabatrin (Sabril): Mechanism of Action, Pharmacokinetics, and Safety Monitoring
3
Belzutifan (WELIREG) Treatment Guide: Duration, Onset of Action, and Monitoring Protocol
4
Lapatinib Side Effects: Managing Diarrhea, Skin Reactions, and Liver Function Changes
5
Trelagliptin: A Once-Weekly Long-Acting Oral DPP-4 Inhibitor
6
Neurokinin Receptor Antagonists: A Non-Hormonal Approach to Menopausal Hot Flashes and Sleep Disturbances
7
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
8
Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression
9
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
10
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
11
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
12
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management